

UPDATE FOR DELISTING PROCESS

On 8 January 2019 the shareholders of ITL Health Group Limited ("ITL") voted overwhelmingly to delist from the official list of the ASX as announced to the market that day.

Pursuant to LR 17.2 ITL is required to send to the ASX a request for suspension from trading to finalise this process.

Please be informed that ITL intends to do this on the 8th February 2019 in line with the conditions imposed by the ASX. This means the last day of trading of ITL shares on the ASX will be that day.

About ITL Health Group www.itlhealthgroup.com

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.

ITL Health Group

ITL is an innovative global medical technology company comprising two divisions; ITL BioMedical and MyHealthTest. ITL holds an IP portfolio of more than 50 patents and sells into 55 countries.

ITL BioMedical creates and manufactures leading edge medical devices for the global blood industry including products for the clinical, blood banking, and laboratory markets. ITL is a growing provider of specialist ancillary products for the Blood Culture Testing and Blood Stream Infection Prevention markets.

MyHealthTest is developing a disruptive business model in the pathology testing market and is building an innovative platform for driving and leveraging the direct to consumer healthcare revolution.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange

Code: ITD

Ordinary Shares

80,819,226

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Chief Financial Officer & Company Secretary
---------------	--

ITL Contact

Trevor Doolan	Company Secretary
Phone:	+61 3 9088 7991
Email:	info@itlhealthgroup.com
Address:	Level 3, 10 Moore Street, Canberra, ACT 2601

www.itlhealthgroup.com

Media

Walbrook IR	Ben Knowles
Phone:	+61 426 277 760
Email:	ben.knowles@walbrookir.co.au